TY - JOUR T1 - r肺纤维化量表(PF):一种简单的、可视的工具评估健康相关的生活质量的JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.00917 -2021欧元SP - 2100917 AU Scallan Ciaran AU -链,劳伦AU -海耶斯,詹妮弗盟——Kadura苏哈AU -柯林斯,布丽姬特盟- Ho,劳伦斯AU -位咨询专家,卡罗琳AU - Canestaro,将非盟-科尔布,特发性肺纤维化(IPF)患者的健康相关生活质量(HRQoL)受损。已经开发了一些工具来客观评估这一患者群体的HRQoL，但没有一种工具在常规临床实践中使用。目的开发一种快速、特异的IPF诊断工具，用于IPF患者的常规临床检查。方法开发了一种全新的、简单的5项数字评分量表(NRS)，并与其他两种已验证的工具进行了比较。100名连续在ILD中心治疗的IPF患者被招募来完成r - pf量表、Kings Brief间质性肺疾病问卷(K-BILD)和EuroQol 5维5水平问卷(eq - 5d - 5l)，以及肺功能和6分钟步行试验。测量和主要结果所有100例患者成功地完成了三个HRQoL工具，其中53例在随访中再次完成。内部一致性高(Cronbach’s α 0.825)，最低限度/上限效应。与K-BILD量表(r=−0.713)和EQ-5D-5 L量表(r=−0.665)相比，r - scale - pf量表的并发效度为中到高。同时效度中等的生理测量(强迫肺活量，r= - 0.307, 6分钟步行距离，r= - 0.383)。R-Scale-PF在比较不同疾病严重程度阶段的分数时显示了良好的已知组效度。结论R-Scale-PF与K-BILD和eq - 5d - 5l有较好的相关性。 It is hoped that this novel simple NRS tool subject to validation in patients from other centers will provide the opportunity to objectively measure HRQoL in routine clinical practice for patients with IPF.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Scallan has nothing to disclose.Conflict of interest: Dr. Strand has nothing to disclose.Conflict of interest: Dr. Hayes has nothing to disclose.Conflict of interest: Dr. Kadura has nothing to disclose.Conflict of interest: Dr. Collins reports personal fees from Boehringer Ingelheim, outside the submitted work; .Conflict of interest: Dr. Ho has nothing to disclose.Conflict of interest: Dr. Spada has nothing to disclose.Conflict of interest: Dr. Canestaro has nothing to disclose.Conflict of interest: Dr. Kolb reports grants from Canadian Pulmonary Fibrosis Foundation, other from Roche, other from Boehringer Ingelheim, grants from Canadian Institute for Health Research, grants and personal fees from Boehringer Ingelheim, grants and personal fees from Roche, grants and personal fees from Liminal, other from European Respiratory Journal, personal fees from Third Pole, personal fees from MitoImmune, grants and personal fees from Pieris, personal fees from Abbvie, personal fees from DevPro Biopharma, personal fees from Horizon, personal fees from Algernon, personal fees from CSL Behring, outside the submitted work; .Conflict of interest: Dr. Raghu has nothing to disclose. ER -